Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.

Yongjian ZhouChunling ZengXiaofeng SunJun ZhangHongyan QuXinhua ZhangYe ZhouZimin LiuXiaojun WuXin WuXuelong JiaoLin ShenYanbing ZhouYuexiang WangJian Li

Published in: The oncologist (2023)

Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.

Keyphrases

drug resistant
multidrug resistant
squamous cell carcinoma
small cell lung cancer
acinetobacter baumannii
clinical trial
cross sectional
pseudomonas aeruginosa
cell therapy
smoking cessation
replacement therapy